StockNews.AI
MRNA
StockNews.AI
22 days

Moderna Announces Data to be Presented at ESMO Congress 2025

1. Moderna will present three abstracts at the 2025 ESMO Congress. 2. mRNA-4359 targets T-cell immune responses in tumors. 3. Intismeran autogene is being developed with Merck for cancer therapies. 4. Moderna will host an analyst event during the Congress. 5. mRNA technology enables rapid development of various therapeutics.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentations could generate investor interest, similar to past news on clinical trials that improved MRNA's stock performance.

How important is it?

The acceptance of key abstracts indicates research progress, which aligns with investor optimism about MRNA's future developments.

Why Long Term?

The outcomes of the presentations and further data announced at ESMO may take time to influence stock performance significantly, reflecting ongoing developments in drug therapies.

Related Companies

MRKBMYGENE
Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157). Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.The details of the presentations are as follows:Presentation #1515MO: Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) MelanomaMini Oral Presentation: October 17, 2025, 2:00 - 3:30 PM CETLocation: Nuremberg Auditorium - Hall 5.2Presenter: David J. PinatoPresentation #3135eTiP: INTerpath-011: Phase 2 study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)​Presenter: Petros GrivasPresentation #1684TiP: Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: the phase 2 INTerpath-012 studyPresenter: Paolo A. AsciertoModerna Investor EventModerna will host an analyst event while at ESMO. Details of the event to follow.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.Moderna ContactsMedia:Chris RidleyHead of Global Media Relations+1 617-800-3651[email protected]Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834[email protected]SOURCE: Moderna, Inc.

Related News